Novel inhibitors of the PI3K family

Bibliography

• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19
   PubMed Web of Science ®Google Scholar
• Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008;8:187-98
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Ali K, Bilancio A, et al. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 2005;30:194-204
   PubMed Web of Science ®Google Scholar
• Klippel A, Reinhard C, Kavanaugh WM, et al. Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways. Mol Cell Biol 1996;16:4117-27
   PubMed Web of Science ®Google Scholar
• Otsu M, Hiles I, Gout I, et al. Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell 1991;65:91-104
   PubMed Web of Science ®Google Scholar
• Hu P, Margolis B, Skolnik EY, et al. Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors. Mol Cell Biol 1992;12:981-90
   PubMed Web of Science ®Google Scholar
• Rodriguez-Viciana P, Downward J. Ras activation of phosphatidylinositol 3-kinase and Akt. Methods Enzymol 2001;333:37-44
   PubMed Web of Science ®Google Scholar
• Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994;370:527-32
   PubMed Web of Science ®Google Scholar
• Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 1998;67:481-507
   PubMed Web of Science ®Google Scholar
• Backer JM. The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem J 2008;410:1-17
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Leevers SJ, Ahmadi K, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001;70:535-602
   PubMed Web of Science ®Google Scholar
• Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7
   PubMed Web of Science ®Google Scholar
• Kuruvilla FG, Schreiber SL. The PIK-related kinases intercept conventional signaling pathways. Chem Biol 1999;6:R129-136
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501
   PubMed Web of Science ®Google Scholar
• Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004;3:1221-4
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554
   PubMed Web of Science ®Google Scholar
• Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 2008;105:2652-7
   PubMed Web of Science ®Google Scholar
• Available from: http://www.sanger.ac.uk/genetics/CGP/cosmic
   Google Scholar
• Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008;27:5486-96
   PubMed Web of Science ®Google Scholar
• Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 2007;104:5569-74
   PubMed Web of Science ®Google Scholar
• Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005;102:802-7
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Liu Z, Wang L, et al. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 2005;102:18443-8
   PubMed Web of Science ®Google Scholar
• Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005;65:10992-1000
   PubMed Web of Science ®Google Scholar
• Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005;65:4562-7
   PubMed Web of Science ®Google Scholar
• Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102
   PubMed Web of Science ®Google Scholar
• Sun M, Paciga JE, Feldman RI, et al. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 2001;61:5985-91
   PubMed Web of Science ®Google Scholar
• Moscatello DK, Holgado-Madruga M, Emlet DR, et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998;273:200-6
   PubMed Web of Science ®Google Scholar
• Jimenez C, Jones DR, Rodriguez-Viciana P, et al. Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J 1998;17:743-53
   PubMed Web of Science ®Google Scholar
• Jucker M, Sudel K, Horn S, et al. Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia 2002;16:894-901
   PubMed Web of Science ®Google Scholar
• Borlado LR, Redondo C, Alvarez B, et al. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J 2000;14:895-903
   PubMed Web of Science ®Google Scholar
• Jia S, Liu Z, Zhang S, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008;454:776-9
   PubMed Web of Science ®Google Scholar
• Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006;125:733-47
   PubMed Web of Science ®Google Scholar
• Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006;103:1475-9
   PubMed Web of Science ®Google Scholar
• Benistant C, Chapuis H, Roche S. A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 2000;19:5083-90
   PubMed Web of Science ®Google Scholar
• Hickey FB, Cotter TG. BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance. J Biol Chem 2006;281:2441-50
   PubMed Web of Science ®Google Scholar
• Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997;16:6151-61
   PubMed Web of Science ®Google Scholar
• Mizoguchi M, Nutt CL, Mohapatra G, Louis DN. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol 2004;14:372-7
   PubMed Web of Science ®Google Scholar
• Sujobert P, Bardet V, Cornillet-Lefebvre P, et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005;106:1063-6
   PubMed Web of Science ®Google Scholar
• Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999;91:1922-32
   PubMed Web of Science ®Google Scholar
• Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007;28:1379-86
   PubMed Web of Science ®Google Scholar
• Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005;436:792
   PubMed Web of Science ®Google Scholar
• Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16:64-7
   PubMed Web of Science ®Google Scholar
• Marsh DJ, Kum JB, Lunetta KL, et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999;8:1461-72
   PubMed Web of Science ®Google Scholar
• Nelen MR, van Staveren WC, Peeters EA, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 1997;6:1383-7
   PubMed Web of Science ®Google Scholar
• Schrager CA, Schneider D, Gruener AC, et al. Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognized syndrome with an increased risk of breast cancer. Hum Pathol 1998;29:47-53
   PubMed Web of Science ®Google Scholar
• Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol 2004;15:171-6
   PubMed Web of Science ®Google Scholar
• Rubin MA, Gerstein A, Reid K, et al. 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer. Hum Pathol 2000;31:504-8
   PubMed Web of Science ®Google Scholar
• Kibel AS, Freije D, Isaacs WB, Bova GS. Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosomes Cancer 1999;25:270-6
   PubMed Web of Science ®Google Scholar
• Pourmand G, Ziaee AA, Abedi AR, et al. Role of PTEN gene in progression of prostate cancer. Urol J 2007;4:95-100
   PubMedGoogle Scholar
• Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-44
   PubMed Web of Science ®Google Scholar
• Cheng JQ, Godwin AK, Bellacosa A, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992;89:9267-71
   PubMed Web of Science ®Google Scholar
• Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995;64:280-5
   PubMed Web of Science ®Google Scholar
• Thompson FH, Nelson MA, Trent JM, et al. Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies. Cancer Genet Cytogenet 1996;87:55-62
   PubMed Web of Science ®Google Scholar
• Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987;84:5034-7
   PubMed Web of Science ®Google Scholar
• Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004;64:7002-10
   PubMed Web of Science ®Google Scholar
• Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-510
   PubMed Web of Science ®Google Scholar
• Gupta S, Ramjaun AR, Haiko P, et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 2007;129:957-68
   PubMed Web of Science ®Google Scholar
• Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-6
   PubMed Web of Science ®Google Scholar
• Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402
   PubMed Web of Science ®Google Scholar
• Lu CH, Wyszomierski SL, Tseng LM, et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007;13:5883-8
   PubMed Web of Science ®Google Scholar
• Eichhorn PJ, Gili M, Scaltriti M, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008;68:9221-30
   PubMed Web of Science ®Google Scholar
• Hamada K, Sasaki T, Koni PA, et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 2005;19:2054-65
   PubMed Web of Science ®Google Scholar
• Yuan TL, Choi HS, Matsui A, et al. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc Natl Acad Sci USA 2008;105:9739-44
   PubMed Web of Science ®Google Scholar
• Graupera M, Guillermet-Guibert J, Foukas LC, et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008;453:662-6
   PubMed Web of Science ®Google Scholar
• Gharbi SI, Zvelebil MJ, Shuttleworth SJ, et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 2007;404:15-21
   PubMed Web of Science ®Google Scholar
• Garlich JR, De P, Dey N, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 2008;68:206-15
   PubMed Web of Science ®Google Scholar
• Knight ZA, Chiang GG, Alaimo PJ, et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem 2004;12:4749-59
   PubMed Web of Science ®Google Scholar
• Carnero A, Lacal JC. Wortmannin, an inhibitor of phosphatidyl-inositol 3-kinase, induces oocyte maturation through a MPF-MAPK-dependent pathway. FEBS Lett 1998;422:155-9
   PubMed Web of Science ®Google Scholar
• Berrie CP. Phosphoinositide 3-kinase inhibition in cancer treatment. Expert Opin Invest Drugs 2001;10:1085-98
   PubMed Web of Science ®Google Scholar
• Stauffer F, Holzer P, Garcia-Echeverria C. Blocking the PI3K/PKB pathway in tumor cells. Curr Med Chem Anticancer Agents 2005;5:449-62
   PubMedGoogle Scholar
• Zhu T, Gu J, Yu K, et al. Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models. J Med Chem 2006;49:1373-8
   PubMed Web of Science ®Google Scholar
• Ihle NT, Williams R, Chow S, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004;3:763-72
   PubMed Web of Science ®Google Scholar
• Ihle NT, Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 2009;8:1-9
   PubMed Web of Science ®Google Scholar
• Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008;27:5511-26
   PubMed Web of Science ®Google Scholar
• Billottet C, Grandage VL, Gale RE, et al. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 2006;25:6648-59
   PubMed Web of Science ®Google Scholar
• Doukas J, Wrasidlo W, Noronha G, et al. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction. Biochem Soc Trans 2007;35:204-6
   PubMed Web of Science ®Google Scholar
• Doukas J, Wrasidlo W, Noronha G, et al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci USA 2006;103:19866-71
   PubMed Web of Science ®Google Scholar
• Fan QW, Cheng CK, Nicolaides TP, et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 2007;67:7960-5
   PubMed Web of Science ®Google Scholar
• Raynaud FI, Eccles S, Clarke PA, et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007;67:5840-50
   PubMed Web of Science ®Google Scholar
• Chen JS, Zhou LJ, Entin-Meer M, et al. Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther 2008;7:841-50
   PubMed Web of Science ®Google Scholar
• Folkes AJ, Ahmadi K, Alderton WK, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin -4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008;51:5522-32
   PubMed Web of Science ®Google Scholar
• Yaguchi S, Fukui Y, Koshimizu I, et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006;98:545-56
   PubMed Web of Science ®Google Scholar
• Kong D, Okamura M, Yoshimi H, Yamori T. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor. Eur J Cancer 2009;45:857-65
   PubMed Web of Science ®Google Scholar
• Dan S, Yoshimi H, Okamura M, et al. Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest. Biochem Biophys Res Commun 2009;379:104-9
   PubMed Web of Science ®Google Scholar
• Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851-63
   PubMed Web of Science ®Google Scholar
• Schnell CR, Stauffer F, Allegrini PR, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008;68:6598-607
   PubMed Web of Science ®Google Scholar
• Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022-30
   PubMed Web of Science ®Google Scholar
• Laird D. XL765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibition of PI3K and mTOR. In AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics B250, 2007
   Google Scholar
• Foster PG. Potentiating the Antitumor Effects of Chemotherapy with the Selective PI3K inhibitor XL147. In AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. C199, 2007
   Google Scholar
• Calvo E, Edelman G, Baselga J, et al. A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors. In EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics. Geneva, Switzerland, 2008
   Google Scholar
• Markman B, Lorusso PM, Patnaik A, et al. A Phase 1 Dose-escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors. In EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics. Geneva, Switzerland, 2008
   Google Scholar
• Macoritto M, Laifenfeld D, Catlett N, et al. PI3K inhibition by GSK1059615B treatment leads to decreased proliferation of human cancer cells by three distinct yet overlapping mechanisms identified by reverse causal reasoning. In AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Geneva, Switzerland, 2008
   Google Scholar
• Camps M, Ruckle T, Ji H, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005;11:936-43
   PubMed Web of Science ®Google Scholar
• Patel RK, Mohan C. PI3K/AKT signaling and systemic autoimmunity. Immunol Res 2005;31:47-55
   PubMed Web of Science ®Google Scholar
• Barber DF, Bartolome A, Hernandez C, et al. Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion. J Immunol 2006;176:589-93
   PubMed Web of Science ®Google Scholar
• Barber DF, Bartolome A, Hernandez C, et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005;11:933-5
   PubMed Web of Science ®Google Scholar
• Oudit GY, Penninger JM. Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res 2009;82:250-60
   PubMed Web of Science ®Google Scholar
• Oudit GY, Sun H, Kerfant BG, et al. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004;37:449-71
   PubMed Web of Science ®Google Scholar
• Crackower MA, Oudit GY, Kozieradzki I, et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002;110:737-49
   PubMed Web of Science ®Google Scholar
• Patrucco E, Notte A, Barberis L, et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 2004;118:375-87
   PubMed Web of Science ®Google Scholar
• Perrino C, Rockman HA, Chiariello M. Targeted inhibition of phosphoinositide 3-kinase activity as a novel strategy to normalize beta-adrenergic receptor function in heart failure. Vascul Pharmacol 2006;45:77-85
   PubMed Web of Science ®Google Scholar
• Niswender KD, Morton GJ, Stearns WH, et al. Intracellular signalling. Key enzyme in leptin-induced anorexia. Nature 2001;413:794-5
   PubMed Web of Science ®Google Scholar
• Hill JW, Williams KW, Ye C, et al. Acute effects of leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons in mice. J Clin Invest 2008;118:1796-805
   PubMed Web of Science ®Google Scholar
• Knight ZA, Shokat KM. Chemically targeting the PI3K family. Biochem Soc Trans 2007;35:245-9
   PubMed Web of Science ®Google Scholar
• Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007;12:487-502
   PubMed Web of Science ®Google Scholar
• Collis SJ, DeWeese TL, Jeggo PA, Parker AR. The life and death of DNA-PK. Oncogene 2005;24:949-61
   PubMed Web of Science ®Google Scholar
• Burma S, Chen DJ. Role of DNA-PK in the cellular response to DNA double-strand breaks. DNA Repair (Amst) 2004;3:909-18
   PubMed Web of Science ®Google Scholar
• Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22
   PubMed Web of Science ®Google Scholar
• Zunder ER, Knight ZA, Houseman BT, et al. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell 2008;14:180-92
   PubMed Web of Science ®Google Scholar
• Bi L, Okabe I, Bernard DJ, et al. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem 1999;274:10963-8
   PubMed Web of Science ®Google Scholar
• Foukas LC, Claret M, Pearce W, et al. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 2006;441:366-70
   PubMed Web of Science ®Google Scholar
• Bi L, Okabe I, Bernard DJ, Nussbaum RL. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome 2002;13:169-72
   PubMed Web of Science ®Google Scholar
• Ihle NT, Paine-Murrieta G, Berggren MI, et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005;4:1349-57
   PubMed Web of Science ®Google Scholar
• Shioi T, Kang PM, Douglas PS, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 2000;19:2537-48
   PubMed Web of Science ®Google Scholar
• McMullen JR, Shioi T, Zhang L, et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 2003;100:12355-60
   PubMed Web of Science ®Google Scholar
• McMullen JR, Jennings GL. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 2007;34:255-62
   PubMed Web of Science ®Google Scholar
• McMullen JR, Amirahmadi F, Woodcock EA, et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 2007;104:612-7
   PubMed Web of Science ®Google Scholar